

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.(currently amended) The PTPRK_{Gly677→Arg682} immunogenic peptide of SEQ ID NO: ~~N-~~ 1.

2.(original) A monoclonal or polyclonal antibody, or an active fragment thereof, which selectively binds the peptide of claim 1.

3.(original) An isolated nucleic acid molecule encoding the peptide of claim 1.

4.(original) An expression vector carrying the nucleic acid molecule of claim 3.

5.(original) A host cell containing the vector of claim 4.

6. (currently amended) An isolated CD4+ T lymphocyte able to selectively recognize and bind the peptide SEQ ID NO: ~~N-~~ 1 associated to a HLA-Class II molecule.

7.(original) A T lymphocyte according to claim 6, which selectively recognizes and binds a peptide/HLA-DR β 1*1001 complex.

8. (currently amended) Antigen presenting cells carrying the peptide SEQ ID NO: N- 1 bound to a HLA-DR β 1*1001 molecule.

9. (currently amended) Pharmaceutical composition containing the peptide SEQ ID NO: N- 1 or a nucleic acid molecule encoding it, in admixture with pharmaceutically acceptable excipients.

10. (original) The pharmaceutical composition of claim 9, in the form of a vaccine.

11. (currently amended) A medicament for the preventive or therapeutic treatment of cancer comprising one of peptide SEQ ID NO: N- 1 and nucleic acid molecules encoding it.

12. (previously presented) The medicament claimed in claim 11, for the preventive or therapeutic treatment of melanoma expressing PTPRK_{Gly677→Arg682}.

13. (currently amended) A diagnostic composition comprising peptide SEQ ID NO: N- 1 or of a nucleic acid molecule encoding it.

14. (previously presented) The composition according to claim 13, wherein said diagnostic composition is utilized in the characterization of melanoma expressing PTPRK_{Gly677→Arg682}.